Get the Stockscreener App
58.03
8.24%
4.42
After Hours:
58.03
Monopar Therapeutics Inc stock is traded at $58.03, with a volume of 97,768.
It is up +8.24% in the last 24 hours and up +0.73% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
See More
Previous Close:
$53.61
Open:
$55.64
24h Volume:
97,768
Relative Volume:
0.41
Market Cap:
$388.34M
Revenue:
-
Net Income/Loss:
$-13.72M
P/E Ratio:
-29.22
EPS:
-1.9861
Net Cash Flow:
$-12.20M
1W Performance:
+4.77%
1M Performance:
+0.73%
6M Performance:
-41.13%
1Y Performance:
+100.66%
1-Day Range:
$54.79
$58.13
1-Week Range:
$50.47
$58.13
52-Week Range:
$26.05
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
58.03 | 358.77M | 0 | -13.72M | -12.20M | -1.9861 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst - defenseworld.net
Monopar Therapeutics Inc (MNPR) Gets a Buy from JonesTrading - theglobeandmail.com
Monopar Therapeutics Shows Rising Relative Strength; Still Shy Of Key Threshold - Investor's Business Daily
Gains Report: Will Monopar Therapeutics Inc benefit from sector rotationQuarterly Trade Review & Long Hold Capital Preservation Plans - baoquankhu1.vn
Trading Systems Reacting to (MNPR) Volatility - Stock Traders Daily
MNPR Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Monopar Therapeutics Inc. (1IY0.SG) stock price, news, quote and history - Yahoo Finance Singapore
[Form 4] Monopar Therapeutics Insider Trading Activity - Stock Titan
Monopar Therapeutics (MNPR) COO gains shares through RSU vesting and tax withholding - Stock Titan
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - chartmill.com
Monopar Therapeutics Inc. 2025 Annual Report Amendment: Financial Highlights, Corrections, and Key SEC Filings - Minichart
Monopar Therapeutics | 10-K/A: Annual report (Amendment) - Moomoo
Monopar (NASDAQ: MNPR) 10-K/A shows $13.7M loss but strong cash - Stock Titan
HC Wainwright Brokers Reduce Earnings Estimates for MNPR - MarketBeat
Monopar Therapeutics Inc. (1IY0.SG) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street - theglobeandmail.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
MNPR SEC FilingsMonopar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MNPR's Rating Maintains 'Buy' by Chardan Capital: March 30, 2026 - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Monopar Therapeutics stock price target maintained at $104 by BTIG - Investing.com Canada
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $104 - Moomoo
Monopar Therapeutics Inc. Q4 and Full Year 2025 Earnings: Net Loss Narrows to $13.7M - Bayelsa Watch
Monopar Therapeutics (STU:1IY0) NonCurrent Deferred Revenue : €0.00 Mil (As of Sep. 2025) - gurufocus.com
Leerink reiterates Monopar stock rating on Wilson disease drug potential By Investing.com - Investing.com Canada
Raymond James reiterates Monopar stock rating on NDA timing shift By Investing.com - Investing.com Canada
Is Flanigans Enterprises Inc stock a hidden gem2026 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MNPR: ALXN1840 advances toward NDA in 2026 as financials improve and cash reserves strengthen - TradingView
Monopar (NASDAQ: MNPR) details 2025 loss and ALXN1840 NDA plan - Stock Titan
Monopar Therapeutics (NASDAQ:MNPR) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - The Manila Times
Monopar Therapeutics Q4 net loss narrows on lower R&D costs - TradingView
Monopar (NASDAQ: MNPR) 10-K outlines ALXN1840 deal, pipeline and runway - Stock Titan
Monopar Therapeutics Inc. Reports Q4 and Full-Year 2025 Financial Results and Highlights Progress for ALXN1840 in Wilson Disease - Quiver Quantitative
Monopar Therapeutics 10‑K: Net loss $13.7M, EPS $(1.85) with operating loss $(16.7M) - TradingView
MNPR: Year-end cash of $140.4M supports ongoing ALXN1840 and MNPR-101 trials; net loss was $13.7M - TradingView
Wilson disease drug heads for mid-2026 filing as Monopar cash lasts to 2027 - Stock Titan
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy - MSN
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
How Monopar Therapeutics Inc. (MNPR) Affects Rotational Strategy Timing - Stock Traders Daily
Monopar Therapeutics (MNPR) to Release Earnings on Monday - MarketBeat
US Stocks Recap: Why is Monopar Therapeutics Inc stock going downProduct Launch & Safe Swing Trade Setups - baoquankhu1.vn
BTIG Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Monopar Therapeutics Aktie: Positive Phase 1b Data for ALXN-802 Sparks Biotech Rally on Nasdaq - AD HOC NEWS
Jones Trading Downgrades Monopar Therapeutics (MNPR) - MSN
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC - MarketBeat
(MNPR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BTIG Reiterates Buy Rating on Monopar Therapeutics (MNPR) | MNPR Stock News - GuruFocus
Published on: 2026-03-07 04:32:52 - baoquankhu1.vn
Monopar Therapeutics (MNPR) officer Susan Rodriguez submits initial Form 3 - Stock Titan
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):